Nestlé swallows US medical nutrition firm
Swiss-based Nestlé has acquired Pamlab, a US-based company specialized in medical nutrition, as the the world's biggest food company pushes further into what it considers a growth segment.
Nestlé, based in Vevey in the canton of Vaud, said on Tuesday that the acquisition was carried out by its fully-owned subsidiary Nestlé Health Science.
Medical nutrition is one of Nestle's growth-drivers and the Pamlab acquisition follows several buys in the field in 2012, including the purchase of Acera, a US company that specializes in nutrition for patients with Alzheimers disease.
"The acquisition of the Pamlab business is aligned with our strategic ambition to provide science-based nutritional solutions for people with chronic medical conditions," said Luis Cantarell, president and chief
executive of Nestlé Health Science, in a statement.
"Pamlab will particularly strengthen our brain health platform and provide us an additional foothold in metabolic health in the US," he said.
Pamlab's portfolio includes product formulated to meet the nutritional requirements of patients with diabetes to help restore the metabolic processes associated with the condition of peripheral neuropathy.
The serious condition is common among those with Type 2 Diabetes, where the patient's peripheral blood flow has been compromised and their nerves damaged.
Founded in 1987 and based in Louisiana, Pamlab employs 300 people.
Comments
See Also
Nestlé, based in Vevey in the canton of Vaud, said on Tuesday that the acquisition was carried out by its fully-owned subsidiary Nestlé Health Science.
Medical nutrition is one of Nestle's growth-drivers and the Pamlab acquisition follows several buys in the field in 2012, including the purchase of Acera, a US company that specializes in nutrition for patients with Alzheimers disease.
"The acquisition of the Pamlab business is aligned with our strategic ambition to provide science-based nutritional solutions for people with chronic medical conditions," said Luis Cantarell, president and chief
executive of Nestlé Health Science, in a statement.
"Pamlab will particularly strengthen our brain health platform and provide us an additional foothold in metabolic health in the US," he said.
Pamlab's portfolio includes product formulated to meet the nutritional requirements of patients with diabetes to help restore the metabolic processes associated with the condition of peripheral neuropathy.
The serious condition is common among those with Type 2 Diabetes, where the patient's peripheral blood flow has been compromised and their nerves damaged.
Founded in 1987 and based in Louisiana, Pamlab employs 300 people.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.